Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Sangamo’s first gene-editing trial doesn’t convince investors

Market spooked by inconclusive early results

- PMLiVE

Money, sex and power

What really makes your world go round? Is it money, sex or power? Or is it something more subtle?

Page & Page Health

- PMLiVE

Genetic counsellors: the new healthcare influencers?

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

Blue Latitude Health

- PMLiVE

The Creative Floor reveal finalists, Lucid’s Louise Verrall hosts pitch session and Star celebrates 16 years

Healthcare Comms news

- PMLiVE

Novartis’ CAR-T Kymriah gets green light in England

Speedy decision contrasts with NICE's 'no' to rival Yescarta in larger adult DLBCL population

- PMLiVE

Ashfield, Health Unlimited and Ashley Communications add to their teams

The latest med comms movers

- PMLiVE

NICE U-turn on Crystiva for rare bone disease

Watchdog to back the drug to treat young people with XLH

- PMLiVE

Home-grown colorectal cancer drug approved in China

Major milestone for China's R&D-based companies

- PMLiVE

Joint Working That Works

Claire Munro blogs about a recent Dovetail workshop on best practice in collaboration between industry and the NHS.

Dovetail

- PMLiVE

PharmaTimes Sales Awards entry deadline approaching soon

Final call for entries as submission date nears

- PMLiVE

Redmile and Google help Evox raise £35.5m for exosome pipeline

It is reported that GV contributed £10m of the total

- PMLiVE

UK start-up Azeria emerges with £4m drug discovery pot for cancer

The company is focusing on hormone resistant breast and prostate cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links